国际医药卫生导报2013，Vol.19Issue(14)：2135-2137,3.DOI:10.3760/cma.j.issn.1007-1245.2013.14.022
噻托溴铵联合沙美特罗/氟替卡松治疗稳定期C组慢性阻塞性肺疾病的疗效评价
Evaluation on therapeutic effects of tiotropium combined with salmeterol and fluticasone in treatment of stable COPD patients of group C
摘要
Abstract
Objective To investigate the therapeutic effects of combination treatment of tiotropium plus salmeterol and fluticasone in the treatment of stable chronic obstructive pulmonary disease (COPD) patients of group C.Methods 60 subjects with stable COPD in group C classified by combined COPD assessment,were randomly divided into a treatment group (n=30) and a control group (n=30).The treatment group was treated with tiotropium(1 8 μ g,inhalation,once daily) plus salmeterol and fluticasone (50,500 μ g,inhalation,twice a day) and the control group was treated only with ipratropium bromide and albuterol aerosol according to the needs.The exercise tolerance and lung function were measured before and 8 weeks after the treatment respectively.Results 8 weeks after the treatment,there were improvements of 6 minute walk test compared with baseline and the control group,significantly greater improvements in the FVC,FEV1 and FEV1％ pred were seen in the treatment group at all time points(P＜O.05).FVC,FEV1 and FEV1％ pred 8 weeks after treatment were higher than those before treatment in both two groups(P＜O.05),but there was a significant difference between the treatment group and the control group (P＜O.05).Conclusion Combination treatment with tiotropium,salmeterol and fluticasone inhalation has greater therapeutic benefits than ipratropium bromide or albuterol aerosol inhalation alone in stable COPD patients of group C.关键词
慢性阻塞性肺疾病/噻托溴铵/沙美特罗/丙酸氟替卡松Key words
Chronic obstructive pulmonary disease (COPD)/Tiotropium/Salmeterol/Fluticasone引用本文复制引用
吕灼荣,房树娟,崔健..噻托溴铵联合沙美特罗/氟替卡松治疗稳定期C组慢性阻塞性肺疾病的疗效评价[J].国际医药卫生导报,2013,19(14):2135-2137,3.
